![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DCN |
Gene summary for DCN |
![]() |
Gene information | Species | Human | Gene symbol | DCN | Gene ID | 1634 |
Gene name | decorin | |
Gene Alias | CSCD | |
Cytomap | 12q21.33 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P07585 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1634 | DCN | CA_HPV_3 | Human | Cervix | CC | 4.52e-35 | 7.84e-01 | 0.0414 |
1634 | DCN | N_HPV_2 | Human | Cervix | N_HPV | 1.22e-14 | 5.18e-01 | -0.0131 |
1634 | DCN | T1 | Human | Cervix | CC | 2.52e-02 | -1.67e-01 | 0.0918 |
1634 | DCN | AEH-subject1 | Human | Endometrium | AEH | 1.52e-43 | -9.66e-01 | -0.3059 |
1634 | DCN | AEH-subject2 | Human | Endometrium | AEH | 7.87e-43 | -1.11e+00 | -0.2525 |
1634 | DCN | AEH-subject3 | Human | Endometrium | AEH | 5.65e-46 | -1.10e+00 | -0.2576 |
1634 | DCN | AEH-subject4 | Human | Endometrium | AEH | 1.13e-08 | -6.38e-01 | -0.2657 |
1634 | DCN | AEH-subject5 | Human | Endometrium | AEH | 2.31e-52 | -1.14e+00 | -0.2953 |
1634 | DCN | EEC-subject1 | Human | Endometrium | EEC | 4.30e-54 | -1.15e+00 | -0.2682 |
1634 | DCN | EEC-subject2 | Human | Endometrium | EEC | 2.14e-57 | -1.18e+00 | -0.2607 |
1634 | DCN | EEC-subject3 | Human | Endometrium | EEC | 4.89e-42 | -9.52e-01 | -0.2525 |
1634 | DCN | EEC-subject4 | Human | Endometrium | EEC | 5.83e-35 | -9.00e-01 | -0.2571 |
1634 | DCN | EEC-subject5 | Human | Endometrium | EEC | 1.09e-49 | -1.09e+00 | -0.249 |
1634 | DCN | GSM5276935 | Human | Endometrium | EEC | 1.70e-54 | -1.14e+00 | -0.123 |
1634 | DCN | GSM5276937 | Human | Endometrium | EEC | 5.72e-14 | -6.91e-01 | -0.0897 |
1634 | DCN | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.21e-44 | -1.19e+00 | -0.1869 |
1634 | DCN | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 4.75e-43 | -1.20e+00 | -0.1875 |
1634 | DCN | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.73e-49 | -1.20e+00 | -0.1883 |
1634 | DCN | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 2.76e-62 | -1.19e+00 | -0.1934 |
1634 | DCN | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 2.62e-65 | -1.20e+00 | -0.1917 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:000989610 | Cervix | CC | positive regulation of catabolic process | 109/2311 | 492/18723 | 5.26e-10 | 6.99e-08 | 109 |
GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
GO:003133110 | Cervix | CC | positive regulation of cellular catabolic process | 91/2311 | 427/18723 | 9.64e-08 | 5.25e-06 | 91 |
GO:00075689 | Cervix | CC | aging | 75/2311 | 339/18723 | 2.75e-07 | 1.13e-05 | 75 |
GO:00018908 | Cervix | CC | placenta development | 40/2311 | 144/18723 | 4.59e-07 | 1.77e-05 | 40 |
GO:00022379 | Cervix | CC | response to molecule of bacterial origin | 78/2311 | 363/18723 | 5.55e-07 | 2.06e-05 | 78 |
GO:00324969 | Cervix | CC | response to lipopolysaccharide | 74/2311 | 343/18723 | 9.15e-07 | 3.25e-05 | 74 |
GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
GO:00435427 | Cervix | CC | endothelial cell migration | 60/2311 | 279/18723 | 1.05e-05 | 2.33e-04 | 60 |
GO:00105944 | Cervix | CC | regulation of endothelial cell migration | 52/2311 | 232/18723 | 1.20e-05 | 2.54e-04 | 52 |
GO:00512713 | Cervix | CC | negative regulation of cellular component movement | 73/2311 | 367/18723 | 2.22e-05 | 3.95e-04 | 73 |
GO:00096127 | Cervix | CC | response to mechanical stimulus | 48/2311 | 216/18723 | 3.23e-05 | 5.29e-04 | 48 |
GO:00400133 | Cervix | CC | negative regulation of locomotion | 76/2311 | 391/18723 | 3.47e-05 | 5.60e-04 | 76 |
GO:20001463 | Cervix | CC | negative regulation of cell motility | 71/2311 | 359/18723 | 3.47e-05 | 5.60e-04 | 71 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa043504 | Endometrium | AEH | TGF-beta signaling pathway | 26/1197 | 108/8465 | 3.82e-03 | 2.18e-02 | 1.59e-02 | 26 |
hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0435011 | Endometrium | AEH | TGF-beta signaling pathway | 26/1197 | 108/8465 | 3.82e-03 | 2.18e-02 | 1.59e-02 | 26 |
hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa043502 | Endometrium | EEC | TGF-beta signaling pathway | 26/1237 | 108/8465 | 5.95e-03 | 3.12e-02 | 2.33e-02 | 26 |
hsa0520534 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa043503 | Endometrium | EEC | TGF-beta signaling pathway | 26/1237 | 108/8465 | 5.95e-03 | 3.12e-02 | 2.33e-02 | 26 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa043507 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0435014 | Esophagus | ESCC | TGF-beta signaling pathway | 69/4205 | 108/8465 | 1.92e-03 | 5.54e-03 | 2.84e-03 | 69 |
hsa0520526 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
hsa043506 | Oral cavity | OSCC | TGF-beta signaling pathway | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa05205111 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
hsa0435013 | Oral cavity | OSCC | TGF-beta signaling pathway | 60/3704 | 108/8465 | 8.66e-03 | 1.97e-02 | 1.00e-02 | 60 |
hsa0520527 | Oral cavity | LP | Proteoglycans in cancer | 77/2418 | 205/8465 | 3.01e-03 | 1.29e-02 | 8.35e-03 | 77 |
hsa0520536 | Oral cavity | LP | Proteoglycans in cancer | 77/2418 | 205/8465 | 3.01e-03 | 1.29e-02 | 8.35e-03 | 77 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DCN | SNV | Missense_Mutation | c.912N>G | p.Ile304Met | p.I304M | P07585 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
DCN | SNV | Missense_Mutation | rs777073492 | c.569N>A | p.Gly190Glu | p.G190E | P07585 | protein_coding | tolerated(0.06) | probably_damaging(1) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DCN | SNV | Missense_Mutation | c.368N>C | p.Gly123Ala | p.G123A | P07585 | protein_coding | tolerated(0.15) | benign(0.003) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
DCN | insertion | Nonsense_Mutation | novel | c.404_405insGTGCTTAACTACAGATATTTTGAGATACC | p.Tyr135Ter | p.Y135* | P07585 | protein_coding | TCGA-A8-A08P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | ||
DCN | insertion | Frame_Shift_Ins | novel | c.390_391insGATATTATAAGGAATAGGAGACTATGTCCAATCACGTTCTGTCAGA | p.Leu131AspfsTer44 | p.L131Dfs*44 | P07585 | protein_coding | TCGA-A8-A09K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
DCN | SNV | Missense_Mutation | novel | c.849N>C | p.Arg283Ser | p.R283S | P07585 | protein_coding | tolerated(0.31) | benign(0.001) | TCGA-AA-3966-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DCN | SNV | Missense_Mutation | c.425N>C | p.Lys142Thr | p.K142T | P07585 | protein_coding | tolerated(1) | benign(0.011) | TCGA-AD-6548-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DCN | SNV | Missense_Mutation | novel | c.449N>C | p.Lys150Thr | p.K150T | P07585 | protein_coding | tolerated(0.07) | possibly_damaging(0.467) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
DCN | SNV | Missense_Mutation | c.283N>A | p.Glu95Lys | p.E95K | P07585 | protein_coding | tolerated(0.09) | probably_damaging(0.995) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
DCN | SNV | Missense_Mutation | c.563N>T | p.Ser188Ile | p.S188I | P07585 | protein_coding | deleterious(0) | probably_damaging(0.921) | TCGA-CK-6746-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1634 | DCN | DRUGGABLE GENOME | IFN | 12707320 | ||
1634 | DCN | DRUGGABLE GENOME | HSP70 | 9292805 | ||
1634 | DCN | DRUGGABLE GENOME | ASCORBIC ACID | 7944410 | ||
1634 | DCN | DRUGGABLE GENOME | RAPAMYCIN | SIROLIMUS | 17200203 |
Page: 1 |